71.40
-0.83%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Siegfried Holding
Its shares trade on SIX under the ticker SFZN.SW. It has been listed since 1 January 1973. In the fiscal year to 31 December 2025, it reported revenue of CHF 1.33bn and net income of CHF 168.7m. At that date it held total assets of CHF 2.15bn and shareholders' equity of CHF 1.13bn.
Siegfried Holding AG engages in the development and manufacture of active pharmaceutical ingredients for pharmaceutical clients with research and development programs, related intermediates, and controlled substances. The company is headquartered in Zofingen, Aargau. The firm produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and steriles. The firm's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The firm operates production facilities in Switzerland, Germany, France, Malta, the United States and China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 1 Jan 1973
- Employees
- 2,407
- Website
- siegfried.ch ↗
Leadership
Pay as last reported
- Dr. Andreas CasuttIndependent Non-Executive Chairman of the Board of DirectorsCHF 484,317
- Mr. Marcel ImwinkelriedChief Executive Officer, Member of the Executive CommitteeCHF 2.0m
- Dr. Martin SchmidIndependent Non-Executive Vice Chairman of the Board of DirectorsCHF 253,793
- Dr. Reto SuterChief Financial Officer, Member of the Executive Committee
- Ms. Olesia SilantevaChief Human Resources Officer, Member of the Executive Committee
- Dr. Stefan RandlChief Scientific Officer, Member of the Executive Committee
- Mr. Peter FreislerChief Business Officer, Member of the Executive Committee
- Mr. Henrik KrupperChief Operating Officer - Drug Substances, Member of the Executive Committee
- Dr. Luca Dalla TorreChief Legal and Sustainability Officer, Member of the Executive Board
- Dr. Alexandra BrandNon-Executive Independent Member of the Board of DirectorsCHF 216,938
- Prof. Dr. Wolfram CariusNon-Executive Independent Member of the Board of DirectorsCHF 221,248
- Ms. Elodie Carr-CingariNon-Executive Independent Member of the Board of DirectorsCHF 227,379
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 79
- Environment
- 74
- Social
- 99
- Governance
- 64
- Direct emissions (scope 1)
- 59,171 t
- Energy emissions (scope 2)
- 12,622 t
- Value chain emissions (scope 3)
- 459,700 t
- Women in the workforce
- 31.6%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Siegfried Holding AG employs 2,407 full-time employees across multiple global locations.
- The company develops and manufactures active pharmaceutical ingredients for hypertension and diabetes treatments.
- Siegfried operates production facilities in Switzerland, Germany, France, Malta, and the United States.
Weaknesses
- Siegfried's drug substances portfolio focuses on specific medical conditions like hypertension and diabetes.
- The company's drug products portfolio includes licensing and contract manufacturing for oral solids and steriles.
- Siegfried's production facilities are spread across six countries including China and the United States.
Opportunities
- Siegfried's drug substances portfolio targets hypertension, benign prostate hyperplasia, and depression treatments.
- The company's drug products portfolio includes contract development for chronic myeloid leukemia and glaucoma treatments.
- Siegfried's global production facilities in Switzerland, Germany, France, Malta, and the United States support international market expansion.
Threats
- Siegfried's drug substances portfolio is limited to specific medical conditions such as asthma and schizophrenia.
- The company's drug products portfolio faces competition in oral solids and steriles manufacturing.
- Siegfried's production facilities in China and the United States may face geopolitical risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.